Analyst Price Targets — MAZE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:12 am | — | Truist Financial | $64.00 | $27.42 | TheFly | Maze Therapeutics price target lowered to $64 from $68 at Truist |
| March 17, 2026 8:06 pm | Danielle Brill | Truist Financial | $68.00 | $50.39 | StreetInsider | Truist Securities Starts Maze Therapeutics (MAZE) at Buy |
| March 10, 2026 8:41 am | — | Mizuho Securities | $97.00 | $51.06 | TheFly | Maze Therapeutics initiated with an Outperform at Mizuho |
| January 19, 2026 5:12 pm | — | BTIG | $46.00 | $40.77 | TheFly | Maze Therapeutics price target raised to $46 from $37 at BTIG |
| December 19, 2025 1:07 pm | Debjit Chattopadhyay | Guggenheim | $46.00 | $41.92 | TheFly | Maze Therapeutics price target raised to $46 from $34 at Guggenheim |
| December 4, 2025 10:32 am | — | Wells Fargo | $55.00 | $41.49 | TheFly | Maze Therapeutics initiated with an Overweight at Wells Fargo |
| December 3, 2025 2:06 pm | — | H.C. Wainwright | $60.00 | $38.75 | TheFly | Maze Therapeutics price target raised to $60 from $50 at H.C. Wainwright |
| November 13, 2025 9:08 pm | — | Raymond James | $48.00 | $31.84 | TheFly | Maze Therapeutics initiated with a Strong Buy at Raymond James |
| September 15, 2025 10:42 am | Debjit Chattopadhyay | Guggenheim | $34.00 | $23.25 | TheFly | Maze Therapeutics price target raised to $34 from $19 at Guggenheim |
| September 2, 2025 10:38 am | — | BTIG | $30.00 | $15.32 | TheFly | Maze Therapeutics initiated with a Buy at BTIG |
Latest News for MAZE
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SOUTH SAN FRANCISCO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph. D. , chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare…
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MAZE.
U.S. House Trading
No House trades found for MAZE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.